Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a "state of metastatic grace" never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the "state of metastatic grace", with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human photoreceptor topography
Curcio, C. A., Sloan, K. R., Kalina, R. E., & Hendrickson, A. E. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902920402 · Cited by 3,167
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 1×
“In 1986, fifteen years after Knudson's initial paper, RB1 was identified as the gene that is the target of two-step mutational inactivation in retinoblastoma (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987).”
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“As most tumors require the inactivation of the p53 pathway as well as the RB pathway (Sherr and McCormick, 2002), the cone precursors' high-level MDM2 expression provided a way to suppress p53 function without mutation of the TP53 gene or MDM2 amplification.”
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Self-citationPharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Kleinerman, R. A., Tucker, M. A., Tarone, R. E., Abramson, D. H., Seddon, J. M., Stovall, M., Li, F. P., & Fraumeni, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.054 · Cited by 487
Dimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle, R. C., Squire, J. A., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn024 · Cited by 351 · cited 5×
“With regard to this hypothesis, non-proliferative RB1−/− retinoma lesions were found to be present at the base of some, and perhaps most, retinoblastoma tumors (Dimaras et al., 2008), suggesting that small retinoma-like lesions might be present but imperceptible at birth and later reactivate to form retinoblastoma tum…”
InfluentialSuprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
Chen, D., Livne-bar, I., Vanderluit, J. L., Slack, R. S., Agochiya, M., & Bremner, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.025 · Cited by 281
One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma
Corson, T. W., & Gallie, B. L. (2007) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20457 · Cited by 278 · cited 3×
“The targets of genomic gains at 1q and 6p are not welldefined, but initial candidates included MDM4, KIF14 on 1q and DEK and E2F3 on 6p (Corson and Gallie, 2007).”
Metadata
- Authors
- Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., Schaiquevich, P., Bergin, C., Dyson, P. J., Houghton, S., Puccinelli, F., Vial, Y., Gaillard, M.-C., & Stathopoulos, C.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 73
- Pages
- 100764
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2948264194
- Cited by
- 215
- References
- 14
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. https://app.cochat.ai/papers/10.1016/j.preteyeres.2019.05.005
- The paper
- Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., Schaiquevich, P., Bergin, C., Dyson, P. J., Houghton, S., Puccinelli, F., Vial, Y., Gaillard, M.-C., & Stathopoulos, C. (2019). Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2019.05.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.